ATC Group: C01CA04 Dopamine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01CA04 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C01 Cardiac therapy
3 C01C Cardiac stimulants excl. cardiac glycosides
4 C01CA Adrenergic and dopaminergic agents
5 C01CA04 Dopamine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 0.5 g

Active ingredients in C01CA04

Active Ingredient Description
Dopamine

Dopamine exerts positive inotropic and chronotropic effects on the myocardium, acting as an agonist at beta-adrenergic receptors. Depending on the vascular bed being studied and the dose administered, dopamine can cause relaxation or contraction of vascular smooth muscle.

Related product monographs

Title Information Source Document Type  
DOPAMINE HYDROCHLORIDE Concentrate for solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Brazil (BR)

Estonia (EE)

Finland (FI)

Hong Kong (HK)

Japan (JP)

Lithuania (LT)

Malta (MT)

Singapore (SG)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.